48,830
edits
(fix typo) |
|||
Line 224: | Line 224: | ||
===Liver versus bile duct=== | ===Liver versus bile duct=== | ||
Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ||
*ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | *ICC: [[CK19]] (92.5%), [[MUC-1]] (73.8%) +ve. | ||
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | *HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | ||
edits